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Background: Blood platelets play an essential role in hemostasis, thrombosis and coagulation of blood. Beyond
these classic functions their involvement in inflammatory, neoplastic and immune processes was also investigated.
It is well known, that platelets have an armament of soluble molecules, factors, mediators, chemokines, cytokines
and neurotransmitters in their granules, and have multiple adhesion molecules and receptors on their surface.
Methods: Selected relevant literature and own views and experiences as clinical observations have been used.
Results: Considering that platelets are indispensable in numerous homeostatic endocrine functions, it is reasonable
to suppose that a platelet-associated regulatory system (PARS) may exist; internal or external triggers and/or stimuli
may complement and connect regulatory pathways aimed towards target tissues and/or cells. The signal (PAF, or
other tissue/cell specific factors) comes from the stimulated (by the e.g., hypophyseal hormones, bacteria, external
factors, etc.) organs or cells, and activates platelets. Platelet activation means their aggregation, sludge formation,
furthermore the release of the for-mentioned biologically very powerful factors, which can locally amplify and
deepen the tissue specific cell reactions. If this process is impaired or inhibited for any reason, the specifically
stimulated organ shows hypofunction. When PARS is upregulated, organ hyperfunction may occur that culminate
in severe diseases.
Conclusion: Based on clinical and experimental evidences we propose that platelets modulate the function of
hypothalamo-hypophyseal-ovarian system. Specifically, hypothalamic GnRH releases FSH from the anterior pituitary,
which induces and stimulates follicular and oocyte maturation and steroid hormone secretion in the ovary. At the
same time follicular cells enhance PAF production. Through these pathways activated platelets are accumulated in
the follicular vessels surrounding the follicle and due to its released soluble molecules (factors, mediators,
chemokines, cytokines, neurotransmitters) locally increase oocyte maturation and hormone secretion. Therefore we
suggest that platelets are not only a small participant but may be the conductor or active mediator of this complex
regulatory system which has several unrevealed mechanisms. In other words platelets are corpuscular messengers,
or are more than a member of the family providing hemostasis.
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Platelets have a volume of 7.1 ± 4.9 μm3, a diameter of
3.6 ± 0.7 μm. They have a surface-connected canalicular
system [1,2] and four distinct populations of granules: α-
granules (containing β-thromboglobulin, platelet factor 4
(PF4), vWF (von Willebrand factor), thrombospondin, fi-
brinogen, albumin, IgG, fibronectin, PDGF (platelet-de-
rived growth factor), and factor V [3-5]), dense bodies
(containig adenine nucleotides, calcium and magnesium,
and serotonin [6,7]), lysosomes, and microperoxisomes.
Granules merge with channels of the canalicular system
after platelet stimulation and evacuate their contents
[8-10]. Platelet have many important surface receptors
(among others GP Ib-IX, GPIIb/IIIa, ICAM-2, P-
selectin, F11R or JAM-A, TLRs, and chemokine recep-
tors [11,12]). The platelet-activating factor (PAF) is also
an important secretory product of platelets mediating
the platelet aggregation, inflammation and anaphylaxis
[13] (Table 1).
Blood platelets play an essential role in hemostasis,
thrombosis and coagulation of blood. The function of
platelets in the maintenance of hemostasis has long beenTable 1 Platelet surface and soluble molecules
Surface molecules Soluble molecules
GP Ib-IX Plasminogen activator in
GP IIb-IIIa α2-antiplasmin
ICAM-2 Fibrinogen
P-selectin Factor V
F11 receptor β-thromboglobulins
TLRs Chemokine RANTES
Chemokine receptors IL-1α
JAM-A IL-1β
JAM-C IL-1RA
CD63 PF4
Benzodiazepine-receptor PAF
EGF
PDGF
Insulin-like growth facto
TGFβ
Thrombospondin
Fibronectin
vWF
ADP
ATP
Histamine
Serotonin
GP Ib-IX, Glycoprotein Ib-IX; GP IIb-IIIa, Glycoprotein IIb-IIIa; ICAM-2, Intercellular adh
Platelet-activating factor; EGF, Epidermal growth factor; PDGF, Platelet-derived grow
ADP, Adenosine diphosphate; ATP, Adenosine triphosphate; DC-SIGN, Dendritic Cell
P-selectin glycoprotein ligand-1.recognized and well defined. Beyond these classic func-
tions their involvement in inflammatory, neoplastic and
immune processes were also investigated by several
reports. Nevertheless, their distinctive armament of
soluble mediators as well as the presence of surface re-
ceptors suggests that platelets must have further roles in
several physiological and pathophysiological regulatory
processes [14].
Platelets have specialized adhesion mechanisms that
make them able to take part in cell-matrix and cell-cell
interactions. This property let platelets arrest bleeding
and promote vessel repair. High shear stress in stenotic
atherosclerotic arteries cause platelet adhesion leading to
the development of arterial thrombosis and cardiovascu-
lar events [15]. The connection between platelets and
cardiovascular diseases has also been proved by the role
of aspirin (by permanent inactivation of COX-1 and −2)
in the prevention of cerebrovascular and cardiovascular
diseases [16].
It has become clear that platelets are not simply cell frag-
ments that plug the leak in a damaged blood vessel; they
are, in fact, also key components in the innate immuneMolecules with effect to platelets
hibitor-1 Fibrinogen
vWF
CD40 ligand
Monoclonal antibody F11
Leukocyte β2 integrin LFA-1
Leukocyte β2 integrin Mac-1
DC-SIGN
PSGL-1
hCG
Progesterone
Estradiol
r 1
esion molecule 2; TLRs, Toll-like receptors; PF4, Platelet factor 4; PAF,
th factor; TGFβ, Transforming growth factor beta; vWF, von Willebrand Factor;
-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin; PSGL-1,
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and cytokines with the ability to modulate the immune sys-
tem through interactions with various cells [17]. Uncon-
trolled or misdirected activation of platelets and the
immune response is involved in the onset and progress of
several conditions with an inflammatory component, such
as coronary artery disease and autoimmune diseases. Direct
interaction between platelets and bacteria leading to platelet
activation has also been reported in several studies in vitro
and in vivo [18,19].
The involvement of platelets and coagulation factors
in tumor progression and metastasis has been exten-
sively documented. Tumor cells are known to interact
with all major components of the hemostatic system, in-
cluding platelets. It has been proved that interrelation-
ship between tumor cells and platelets, within the
bloodstream, is important during the early phase of me-
tastasis [20]. Cancerous patients have increased risk of
thrombosis, and the signs of it are most severe if the dis-
ease has progressed to a metastatic stage [21].
The role of platelets in different endocrine diseases
have already been published. Hyperthyroidism is associ-
ated with increased platelet production [22]. Not only
thyroid but also parathyroid disorders are associated
with hemostatic abnormalities and vascular diseases
[23]. The relationship between platelet function and an
increased occurrence of vascular diseases in diabetic
patients has also been proven. Hyperglycemia can lead
to increased platelet reactivity and not only hypergly-
cemia but insulin can also directly control platelet
function by a functional insulin receptor found on hu-
man platelets [24].
Role of platelets in female reproduction
Platelet aggregation and adhesion to endothelial cells
has been observed in the capillaries around periovula-
tory follicles [25]. Concentrations of TXB2 in the follicu-
lar wall and in follicular fluid were dramatically elevated
in preovulatory follicles. Aggregates of platelets (the sus-
pected source of TXA2) were adhered to endothelial
cells at this time; in some cases intra and extravascular
clotting was apparent. It is suggested that platelets and
(or) TXA2 might contribute to this periovulatory
processes.
The platelet count in the inferior vena cava was sig-
nificantly decreased 48 h after PMSG administration and
was further decreased after hCG administration in im-
mature rats. When both ovaries were extirpated, the ad-
ministration of PMSG and hCG did not decrease the
platelet count. Subcutaneous administration of a PAF
antagonist after PMSG injection decreased the number
of ova shed in a dose-dependent manner. The decrease
in the platelet count induced by the administration of
PMSG and hCG was reversed to the level of theuntreated control group by a PAF antagonist. This in-
hibitory activity of a PAF antagonist on ovulation and
thrombocytopenia was completely reversed by the injec-
tion of a synthetic PAF [26].
Oestrogen has been reported to regulate the plasma
level of PAF-acetylhydrolase activity, and its suppression
by oestrogen leads to the accumulation of PAF in the
ovary [27,28]. It means that PAF synthesis may be medi-
ated by ovarian steroid hormones during ovulation. It is
reported that serotonin and histamine have a direct
stimulatory effect on ovarian steroid synthesis, and it
was suggested that these neurotransmitters may reach
the ovary by platelets which assume a platelet-associated
paracrine-endocrine regulation [29,30].
There are experimental data demonstrating the pres-
ence and actions of various neurotransmitters in the
ovary, thus supporting the view that they might play a
role in intraovarian regulatory mechanisms, although
their exact function in the regulation of ovarian hor-
mone secretion is unclear. We described that serotonin
stimulated a dose-related increase in progesterone secre-
tion, however estradiol secretion in response to sero-
tonin was dose-independent. In cell culture, co-
administration of serotonin with gonadotropins had no
additive effect on gonadotropin-induced secretion of
progesterone, while it further augmented that of estra-
diol. Histamine stimulated a dose-related increase in es-
tradiol secretion with a maximal stimulatory effect.
Progesterone production in response to histamine
stimulation was independent of dose at the limit of sig-
nificance, but histamine had no effect on progesterone
release. We suggest that histamine has a direct stimula-
tory effect on steroid production of granulosa cells me-
diated via the H1-receptor [31,32]. Both serotonin and
histamine are originated from platelets and may have a
physiological role in the corpus hemorrhagicum, when
luteinization is initiated.
The relationship between ovarian function and plate-
lets is also being investigated. The human corpus luteum
is a unique endocrine organ that fills the postovulatory
follicle during the menstrual cycle. Its role is to provide
progesterone to the systemic circulation. Fujiwara used
immunohistochemical procedures to show that consider-
able numbers of platelets and red cells were present at
extravascular sites among luteinizing granulosa cells
after ovulation. Increased vascular permeability beneath
the follicular basement membrane may permit extrava-
sation of blood cells into the spaces around luteinizing
cells. The platelets, activated through adhesion to com-
ponents of the extracellular matrix (collagen?), probably
by the same mechanisms involved in hemostasis,
expressed P-selectin demonstrating that platelet secre-
tion had occurred. In vitro studies showed that proges-
terone production by luteinizing granulosa cells from
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promoted by direct contact with platelets during 4-d
culture. In contrast, platelet-derived soluble factors in-
duced both granulosa cell spreading and endothelial cell
migration, evidence for multiple actions of platelets in
the process of luteinization. An in vivo consequence is
enhanced extracellular matrix formation around the lu-
teal cells and the growth of vascular networks. It has
been previously shown that luteinizing granulosa cells
secrete proangiogenic factors such as vascular endothe-
lial growth factor (VEGF); although VEGF induces endo-
thelial cell proliferation, it does not induce their
migration. Interestingly, it has been shown that when
cocultured with platelets, granulosa cells inhibited endo-
thelial cell migration. Although this could be interpreted
as being contradictory to their hypothesis, the authors
suggest a crucial regulatory role of granulosa cells in
protecting against “overvascularization” and an excessive
stimulatory effect of platelets. The role of platelets in
these events was compared by the authors to their role
and that of coagulation proteins in inflammation.
It is known that an increase in platelet number in ovarian
hyperstimulation syndrome (OHSS) coupled with elevated
blood coagulation factors and hyperviscosity in a severe
form of this syndrome may result in the development of
intravascular thrombosis [33]. OHSS is a severe, potentially
lethal iatrogenic disease, resulting from vasoactive products
released by hyperstimulated ovaries. OHSS is characterized
by increased capillary permeability triggerred by VEGF,
which correlates with increased platelet activation [34]. Ac-
tivated platelets release histamine, serotonin, platelet-
derived growth factor, or lysophosphatidic acid. These sub-
stances might further drive the pathophysiological cascade
leading to OHSS. Based on this we hypothesized that using
aspirin might prevent this syndrome [35]. To prove this, we
randomly administered aspirin to high risk and low risk pa-
tients undergoing in vitro fertilization protocol and deter-
mined the proportion of OHSS in each group. In our study,
among the patients treated with aspirin, there were only 2
occasions of severe or critical OHSS (0.25%). Both patients
belonged to the high risk group. However, among those
high risk patients that received no prophylactic aspirin regi-
men, 43 patients (8.4%) presented OHSS. No OHSS was
encountered in the low risk groups. Since there was a sig-
nificant difference in the occurrence of severe OHSS be-
tween the aspirin treated and non-treated high risk groups,
an overall advantageous effect of aspirin preventing OHSS
might be seen. We strongly advise, therefore, the use of
low-dose aspirin to prevent OHSS or to reduce its severity
in all cases associated with high risk of that severe compli-
cation of ovulation induction.
The coordinated interplay between platelets and ovaries
may be accomplished further by the brain-derived neuro-
trophic factor (BDNF) - Sigma-1 receptor – Akt – eNOSsystem. Down-regulation of the system has been proved to
be a pathogenetic factor for depression, cardiovascular dis-
eases, diabetes mellitus type 2 and for several components
of metabolic syndrome. The activation of Sígma-1R signal-
ing has emerged as a link between these pathologies
[36,37].
BDNF is mainly produced by the brain accounting for
over 70% in the circulation. Additional BDNF sources
are the vascular endothelium, smooth muscle cells and
activated monocytes/lymphocytes. It readily crosses the
blood–brain barrier, circulates in the plasma and is taken
up and stored in the platelets. Upon platelet activation/
clotting BDNF is released to the extracellular fluid and
platelet derived serum BDNF closely correlates with that
in the brain [38,39]. Importantly, positive correlation has
been documented between BDNF and serotonin release
[40,41]. BDNF and serotonin are assumed to act syner-
gistically as serotonin secretion, turnover and signaling
is regulated by BDNF, while serotonin in turn controls
BDNF production [41].
BDNF and its receptors are widely distributed in per-
ipheral tissues and implicated in modulating ovarium
function and diseases related to ovarium dysfunction.
With this contention in line Sigma-1R stimulation with
selective serotonin reuptake inhibitors (SSRI) in ovariec-
tomized animals and in postmenopausal women im-
proved depressive disorders and provided cardiovascular
protection [42]. This beneficial effect of SSRI is achieved
by increased conversion of the precursor proBDNF to
mature BDNF and its enhanced secretion into the extra-
cellular space [43]. Stimulation of Sigma-1R by ovarial
steroids, dehydroepiandrosterone (DHEA) or pregnelo-
lone (PREG) and/or by their sulfates (DHEAS, PREGS)
resulted in similar protection in experimental or clinical
settings [44].
Interestingly, there are marked cyclic variations in
platelet BDNF levels during menstruation. In the second
half of menstrual cycle endometrial cells produce sub-
stantial amount of BDNF which is taken up by the plate-
lets. The reduced accumulation of endometrium-derived
BDNF in the platelets may lead to clinical consequences
as seen in menopausa [45].
In a most recent comprehensive review detailed ana-
lysis is presented on the importance of BDNF in the
paracrine regulation of ovarian function [46]. BDNF has
been shown to stimulate the early and final stage of folli-
culogenesis, oocyte maturation and early embryonic de-
velopment. In women undergoing IVF treatment it was
present in the follicular fluid, and cumulus and granu-
losa cells were identified as its major source. Significant
positive correlation was found between circulating estra-
diol and BDNF levels and its ovarian secretion could be
enhanced with LH, FSH and hCG administration. It is to
be noted that BDNF release by the platelets was not
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ing evidences suggest that platelet-derived mediators
have a prominent role in the intra-ovarian regulation.
The involvement of platelets in the reproductive pro-
cesses is further supported by the observations that hu-
man endometrial tissues and stromal cells in primary
culture contain PDGFs and their receptors. They have
been shown to induce growth, proliferation, motility and
contractility of endometrial stromal cells. It is of note
that several factors, including estrogens increase the tis-
sue expression of PDGF-Rs, consequently they enhance
the local effects of PDGFs [47].
In the followings we give a short summary of our con-
cept concerning the involvement of platelets in modulat-
ing the function of the hypothalamo-hypophyseal-
ovarian system. Considering the data, hypothalamic
GnRH releases FSH from the anterior pituitary, which
induces and stimulates follicular and oocyte maturation
and steroid hormone secretion in the ovary. At the same
time follicular cells enhance PAF production. Through
these pathways activated platelets are accumulated in
the follicular vessels surrounding the follicle and due to
its released soluble molecules (factors, mediators, che-
mokines, cytokines, neurotransmitters) locally increases
oocyte maturation and hormone secretion.Platelets in pregnancy
Platelet’s functions and their role in the coagulation
process in pregnancy are well documented, and there
are several data to suggest their importance in embryo
implantation, placental development, preeclampsia,
HELLP syndrome, and other physiological and patho-
physiological processes.Platelets may play a role in placentation
Circulating platelets stores several bioactive mediators
within their granulas, including PDGF-B, bFGF, HGF,
IGF, IGF-1, PF4, TSP1, TGF-β1 and VEGF, and they re-
lease them upon stimulation. Most of these molecules
are found to be relevant in mouse placentation, for in-
stance bFGF, IGF-1 or PDGF which were proved to be
an effective protector of trophoblast cells against TNF-α
and INF-γ induced apoptosis in vitro [48]. Beyond that,
the deficit of PDGF-B or PDGF-R-β, results vessel dila-
tion in the placenta [49]. Moreover the developmental
failure of the placenta is associated with the absence of
lipid-phosphatase 3 (LLP-3) [50]. Such findings imple-
mented the necessity of in vivo animal experiments to
further investigate the role of platelets in implantation
and development. The mouse model of quantitative
platelet disorder (NF-E2 deficient mice) and qualitative
thrombocyte defect (Gαq, Par-3, or Par-4 deficient mice)
makes them eligible for such task.The NF-E2 transcriptional factor is a crucial protein of
the megakaryopoiesis, therefore NF-E2 “knock-out” mice
develops a severe quantitative platelet deficiency [51].
Such condition in these animals is associated with sig-
nificant intrauterine growth retardation (IUGR), ex-
plained by the vascular abnormality of the placental
labyrinthine layer, due to impaired blood vessel maturity.
Interestingly, failure of the placental vascularization is
only reported in NF-E2 null embryos, but not in NF-E2
null mothers, nor mice with other platelet disorders.
NF-E2 “knock-out” mothers delivers same number of lit-
ter, and the embryonic loss was found to be not signifi-
cantly different compared to wild type mice, despite that
histological evaluation revealed numerous spacious
blood pools in the placenta (intraplacental hemorrhage)
[52,53].
On the other hand, in case of qualitative thrombocyte
abnormalities placental disorders can not be revealed.
For example Gαq-deficient mice (lack of the α-subunit
of the guanine nucleotide binding protein Gq), has nor-
mal number of thrombocytes, but their platelets can not
be activated, develop normal placental development and
embryos [54]. Likewise, when protease-activated recep-
tor 3 and 4 (Par-3 and Par-4) mediated platelet activa-
tion is also missing in mice an intact, normal placenta
and embryo develops [55].
Next to the experimental results from mice, human
data also show that maternal platelets might play im-
portant role in the placental vascular remodeling, which
assures proper placental perfusion and maintains the
pregnancy itself. Such phenomenon is based on the
endovascular invasion of trophoblast cells into the ma-
ternal spiral arteries, enabling them to transform large-
caliber vessels [56]. The mechanism of such alteration is,
that maternal platelets are trapped in the lumen of the
spiral arteries by endovascular trophoblast aggregates.
These activated platelets are communicating with neu-
trophil granulocytes, by expressing P-selectin on their
surfaces. These cell surface cell adhesion molecules are
binding to their ligands (P-selectin glycoprotein ligand-1;
PSGL-1) on the activated granucolcytes, and in turn they
produce PAF to facilitate the further aggregation pro-
cesses [57]. Extravillous trophoblast cells express chemo-
kine receptor (CCR1), which plays as a functional
receptor for trophoblasts. Their ligands (CCR1 ligand)
are secreted by the activated platelets in the placenta to
encourage the remodeling processes, and to attract more
endovascular trophoblasts to the site [58]. To achieve
such vascular caliber changes during the early placenta-
tion a direct contact between the platelets and the
trophoblast cells is not fully required. Therefore it is sus-
pected that some soluble platelet-derived factor(s) are
regulating the placental vascular remodeling processes in
human [58].
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loss, intrauterine growth restriction and preeclampsia,
highlighted the effectiveness of low-dose platelet cyclo-
oxygenase inhibitor (Aspirin®), which reduces the plate-
let aggregation by suppressing the TXA2 synthesis [59].
However, pregnant women with Bernard-Soulier syn-
drome or other congenital thrombocytopenias usually
have an uncomplicated pregnancy and they deliver a
healthy newborn, but the risk for a potential postpartum
bleeding is increased [60].
Platelets in preeclampsia and HELLP syndrome
Pregnancy is a condition of immunological balance be-
tween the mother and her semi-allograft fetus. Besides,
pregnancy is considered as a controlled pro-coagulation,
and a mild inflammatory state. As platelets are involved
in all of these processes, their consumption is enhanced.
Consequently, platelet production is augmented, result-
ing in a slightly increased ratio of young platelets in the
bloodstream. However, platelet count remains normal
(150,000 to 450,000 platelets per microliter) throughout
normal pregnancy. This slim equilibrium will be dis-
turbed in conditions where complex maternal adapta-
tion to her pregnancy is inadequate.
Preeclampsia is a serious disease in pregnancy with
heterogeneous etiology [61,62]. Early-onset, or hypovol-
emic, or serious preeclampsia and the hemolysis, ele-
vated liver enzymes, and low platelet count (HELLP)
syndrome are thought to be conditions due to imbalance
between the mother and fetus [63]. Theoretically, the
progenitors could be of normal fetal antigens but their
pathologically increased mass in the maternal circulation
and/or the abnormal maternal reaction to them (“mal-
adaptation”) could lead to the clinical symptoms. Plate-
lets play a pivotal role in the holistic defending
mechanism, being stimulated in increasing degrees in
these serious diseases. Overstimulation collapses this
platelet-associated regulation contributing to the devel-
opment of end-organ damages.
Early-onset preeclampsia can be considered as a 2-stage
disease. Abnormal placentation (first stage) through endo-
thelial damage is responsible for the potential of end-organ
manifestations (second stage). The first stage is character-
ized by effects of anti-angiogenic substances such as the
soluble fms-like tyrosine kinas-1 (sFlt-1) [64], endoglin
(sEng) [65], and human interferon-inducible protein 10 (IP-
10 or CXC10) [66] which bind and neutralize different
growth factors, placental growth factor (PlGF), VEGF, and
TGF-β required for placental and fetal angiogenesis. Agents
directly from this shallowly implanted placenta and also
from activated leukocytes or platelets may represent the
link between abnormal placentation and endothelial inflam-
matory injury. Recent candidates are the anti-angiogenic
agents; free oxygen radicals and some cytokines, first of allTNF-α [67,68], thrombogenic content of miroparticles re-
leased from the surface of different cells [69]; syncytiotro-
phoblast microvilli or vesicles [70] releasing sFlt-1 and
sEng; fetal cells and cell-free fetal DNA [71] circulating in a
relatively huge amount in preeclamptic maternal blood-
stream. Consequently, markers of endothelial injury e. g. fi-
bronectin [72] soluble thrombomodulin [73], or von
Willebrand factor [74] show elevated levels in preeclampsia.
Similarly, levels of platelet-aggregation products (e.g. β
thromboglobulin, PF4, TXA2) are elevated [75].
Epidemiological studies suggested that “immune-mal-
adaptation” may have an etiologic role in the develop-
ment of preeclampsia [76]. Long (>4 months) maternal
ejaculate-exposition results in slow alloimmunization,
and development of immuntolerance against the given
gentile antibodies [71]. In the absence of appropriate
partner-specific mucosal immuntolerance the incidence
and severity of preeclampsia will increase [77]. Fetal pro-
teins contact with maternal immune system not only at
the feto-maternal interface but also in the maternal cir-
culation, where fetal cells, cell debris, or DNA can be de-
tected in huge number in preeclamptic individuals,
showing correlation with the severity of the disease [71].
Platelets play a pivotal role in the initiation and modula-
tion of immunological processes. Soluble platelet-
released immune modulators (chemokines, cytokines)
coordinate leukocyte migration, endothelial adhesion,
and function [78]. There is no doubt that signals of acti-
vated platelets are essentials in the development of ma-
ternal immune-respose in preeclampsia too.
It is well known for some decades that platelets and
also intravascular coagulation cascade are activated in
preeclampsia. Damaged endothelial cells produce more
adhesive substances (e.g. fibronectin, vascular cell adhe-
sion molecule-1, E-selectin) and possess less antithrom-
botic capacity (e.g. weak thrombomodulin effects) than
normal endothelial cells [73,79]. Impairment of endothe-
lium exposes the subendothelial collagen, a potent
platelet-activating agent, to vessel content. Increased ni-
tric oxide (NO) production during normal pregnancy ef-
fectively decreases the sensitivity of platelets to pro-
aggregating agents [80]. Asymmetric dimethyl arginine
(ADMA), the endogenous inhibitor of NO synthesis,
levels are increased in preeclampsia [81] lowering the ef-
fectiveness of an important protective mechanism of
platelet activation. In accordance, the augmentation of
endogenous and reactive NO production shows benefi-
cial effects in gestational hypertension [82]. Similarly,
damaged endothelial cells produce less prostaglandin I2
(PGI2 or prostacyclin), another potent agent against
platelet activation [83].
Activated platelets not only release the vasoconstrictor
TXA2, but also increase the expression of adhesive
agents [84]. Activated platelets this way enhance further
Figure 1 Hypothetical scheme of platelet-associated regulatory
system (PARS). Note, platelets convey information from the central
nervous system to the ovaries via storing and releasing brain-derived
factors. GnRH: gonadotropine releasing hormone; LH: luteinizing
hormone; FSH: folliculus stimulating hormone; PAF: platelet activating
factor; +: stimulation; − : inhibition, BDNF: brain-derived neurotrophic
factor.
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contact and trigger leukocyte arrest and transendothelial
migration [85].
Erythrocyte deformability has been found to be de-
creased in preeclampsia which may contribute to de-
creased capillary circulation [86], since capillary
diameter is about the half of those of red blood cells.
Peripheral mechanical hemolysis is a hallmark of HELLP
but characteristic feature of severe preeclampsia as well
[87]. Hemolysis in preeclampsia may further enhance
the platelet activation since breaking red blood cells re-
lease ADP [88]. Besides, damaged erythrocytes show an
enhanced aggregability as well [89]. This way altered
hemostasis with activated platelets markedly contributes
to the collapse of microcirculation resulting in tissue hy-
poperfusion with subsequent end-organ dysfunction in
serious preeclampsia.
Platelets actively take part in the defensive action
against pathogenic microorganisms. Platelets quickly ac-
cumulate and become activated at the site of invasion
[90]. They not only release effective agents to damage
invading cells but also capable of eliminate them from
the circulation. The cationic thrombocidins, releasing
from the α granules, are able to depolarize bacterial
membranes and inhibit the synthesis of some intracellu-
lar molecules [91]. Besides, secondary to stimuli by ADP
or stromal cell-derived factor-1 platelets can eliminates
bacteria or viruses by internalization (“engulfment”) [92].
The relationship between preeclampsia and infection
was posed by the preeclampsia model based on low-dose
endotoxin infusion in pregnant rats [93]. Since then sev-
eral studies found correlation between preeclampsia/
HELLP syndrome and different forms of infection:
 Concomitant urogenital infection during pregnancy
enhances the incidence of preeclampsia [94];
 Statistical data confirm that preeclampsia incidence
increases when patients had Chlamydia pneumoniae
infection previously [95];
 Periodontitis during pregnancy predisposes for
preeclampsia [96];
 Use of antibiotics during pregnancy decreases the
incidence of preeclampsia [97];
 In patients with HELLP syndrome a concomitant
infection is frequent [98];
It is tempting to assume that the link between pre-
eclampsia and different inflammations may be further en-
hancing of platelet activation. This presumption seems to
be supported by the modest but obvious efficacy of aspirin
in the prevention of preeclampsia [99]. Besides, bacterial
endotoxin in known to destroy endothelial cells enhancing
their dysfunction. Furthermore, platelet adhesion and ag-
gregation could be the consequence of elevated shear stress[100]. High shear stress is ordinarily caused by hyperten-
sion, which is a criterion of preeclampsia.
Platelet activation in HELLP syndrome has similar back-
ground than it is characteristic for severe preeclampsia;
however, there are some differences. The early trophoblast
lesion is more pronounced in HELLP. The antiangiogenic
sEng levels are significantly higher in HELLP than in pre-
eclampsia. Development of microangiopathy, secondary to
increased sEng, sFlt-1, activated TNFα, and von Willebrand
factor in HELLP may explain the extreme platelet con-
sumption as consequence of overstimulation [63].
In severe preeclampsia and HELLP syndrome platelets
are highly stimulated. Falling the platelet count and ele-
vation of platelet aggregation products precede the
manifestation of clinical symptoms by several weeks
[75]. This stimulation could be enhanced further by con-
comitant infection which worsens the condition. Inhib-
ition of platelet aggregation, starting in first trimester,
may have a beneficial effect. On the contrary, when the
consumption permanently exceeds the production the
platelet-associated regulatory system (PARS) collapses
and the condition turns to critical state.
Conclusion - PARS
The above summarized data and the other relevant litera-
ture have proved that blood platelets play an essential role
in different regulatory processes; among others hemostasis
and thrombosis, inflammatory reactions, malignancies, im-
mune responses and in endocrine regulation. Platelets have
an armament of soluble molecules, factors, mediators, che-
mokines, cytokines and neurotransmitters in their granules,
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their surface. Considering that platelets are indispensable in
numerous homeostatic endocrine functions, it is reasonable
to suppose that a platelet-associated regulatory system
(PARS) may exist; internal or external triggers and/or stim-
uli may complement and connect regulatory pathways
aimed towards target tissues and/or cells. The signal (PAF,
or other tissue/cell specific factors) comes from the stimu-
lated (by the e.g., pituitary hormones, bacteria, external fac-
tors, etc.) organs or cells, and activates platelets. Platelet
activation means their aggregation, sludge formation, fur-
thermore the release of the for-mentioned biologically very
powerful factors, which can locally amplify and deepen the
tissue specific cell reactions. If this process is impaired or
inhibited for any reason, the specifically stimulated organ
shows hypofunction. When PARS is upregulated, organ hy-
perfunction may occur that culminate in severe diseases.
Therefore we suggest that platelets are not only a by-
stander but rather may be the conductor or active medi-
ator of this complex regulatory system which has several
unrevealed mechanisms. In other words platelets are
corpuscular messengers, or are more than a member of
the family providing hemostasis.
The possible existence of PARS has been established
by detailed analysis of relevant litterature, however fur-
ther targeted studies should be conducted to confirm
the concept delineated in this article (Figure 1).
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